文献速递类风湿关节炎

类风湿关节炎患者暂停甲氨蝶呤2周对季节性流感疫苗免疫原性的影响:一项随机临床试验

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
PubMed 文献 · Ann Rheum Dis · 2018-03-23

这项前瞻性随机平行组多中心研究纳入接受稳定剂量甲氨蝶呤的类风湿关节炎患者,按1:1随机分为疫苗接种后继续甲氨蝶呤组或暂停甲氨蝶呤2周组,评估2016-2017年四价季节性流感疫苗的免疫应答。暂停甲氨蝶呤组达到满意疫苗应答的比例高于继续组(75.5% vs 54.5%,p<0.001),四种抗原的血清保护率均更高,抗体滴度倍数增长更高,两组疾病活动度变化相似。

要点

  • 暂停甲氨蝶呤2周组满意疫苗应答率75.5%,继续组54.5%(p<0.001)。
  • 暂停组四种抗原血清保护率均高于继续组,差异10.7%至15.9%。
  • 暂停组四种流感抗原抗体滴度倍数增长均更高(均p<0.05)。

核心结论

  • 疫苗接种后暂停甲氨蝶呤2周可改善类风湿关节炎患者对季节性流感疫苗的免疫原性,且不增加类风湿关节炎疾病活动度。

研究设计与样本

  • 前瞻性随机平行组多中心研究,接受稳定剂量甲氨蝶呤的类风湿关节炎患者按1:1随机分为继续甲氨蝶呤组或疫苗接种后暂停甲氨蝶呤2周组。
  • 接种2016-2017年四价季节性流感疫苗,含H1N1、H3N2、B-Yamagata和B-Victoria。
  • 改良意向治疗人群包括继续甲氨蝶呤组156例和暂停甲氨蝶呤组160例。

主要发现

  • 暂停甲氨蝶呤组达到满意疫苗应答的患者比例高于继续组(75.5% vs 54.5%,p<0.001)。
  • 暂停组血清保护率高于继续组:H1N1差异10.7%(95%CI 2.0%至19.3%),H3N2差异15.9%(95%CI 5.9%至26.0%),B-Yamagata差异13.7%(95%CI 5.2%至22.4%),B-Victoria差异14.7%(95%CI 4.5%至25.0%)。
  • 暂停组针对全部四种流感抗原的抗体滴度倍数增长均更高(均p<0.05)。
  • 两组疾病活动度变化相似。

关键数值与推荐

  • 主要结局为满意疫苗应答,定义为接种后4周血凝抑制抗体滴度对四种疫苗株中至少两种达到≥4倍增长。
  • 次要终点包括血清保护率(血凝抑制抗体滴度≥1:40)和抗体滴度倍数变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether a 2-week methotrexate (MTX) discontinuation after vaccination improves the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA). METHODS: In this prospective randomised parallel-group multicentre study, patients with RA on stable dose of MTX were randomly assigned at a ratio of 1:1 to continue MTX or to hold MTX for 2 weeks after 2016-2017 quadrivalent seasonal influenza vaccine containing H1N1, H3N2, B-Yamagata and B-Victoria. The primary outcome was frequency of satisfactory vaccine response, defined as greater than or equal to fourfold increase of haemagglutination inhibition (HI) antibody titre at 4 weeks after vaccination against ≥2 of four vaccine strains. Secondary endpoints included seroprotection (ie, HI titre ≥1:40) rate, fold change in antibody titres. RESULTS: The modified intention-to-treat population included 156 patients in the MTX-continue group and 160 patients in the MTX-hold group. More patients in MTX-hold group achieved satisfactory vaccine response than the MTX-continue group (75.5% vs 54.5%, p<0.001). Seroprotection rate was higher in the MTX-hold group than the MTX-continue group for all four antigens (H1N1: difference 10.7%, 95% CI 2.0% to 19.3%; H3N2: difference 15.9%, 95% CI 5.9% to 26.0%; B-Yamagata: difference13.7%, 95% CI 5.2% to 22.4%; B-Victoria: difference 14.7%, 95% CI 4.5% to 25.0%). The MTX-hold group showed higher fold increase in their antibody titres against all four influenza antigens (all p<0.05). Change in disease activity was similar between groups. CONCLUSIONS: A temporary MTX discontinuation for 2 weeks after vaccination improves the immunogenicity of seasonal influenza vaccination in patients with RA without increasing RA disease activity. TRIAL REGISTRATION: NCT02897011.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018. PMID: 29572291. doi:10.1136/annrheumdis-2018-213222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。